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Background: Immune markers in the peripheral blood of melanoma patients could provide prognostic information.
However, there is currently no consensus on which circulating cell types have more clinical impact. We therefore
evaluated myeloid-derived suppressor cells (MDSC), dendritic cells (DC), cytotoxic T-cells and regulatory T-cells (Treg) in
a series of blood samples of melanoma patients in different stages of disease.
Methods: Flow cytometry was performed on peripheral blood mononuclear cells of 69 stage I to IV melanoma
patients with a median follow-up of 39 months after diagnosis to measure the percentage of monocytic MDSCs
(mMDSCs), polymorphonuclear MDSCs (pmnMDSCs), myeloid DCs (mDCs), plasmacytoid DCs (pDCs), cytotoxic T-cells
and Tregs. We also assessed the expression of PD-L1 and CTLA-4 in cytotoxic T-cells and Tregs respectively. The impact
of cell frequencies on prognosis was tested with multivariate Cox regression modelling.
Results: Circulating pDC levels were decreased in patients with advanced (P = 0.001) or active (P = 0.002) disease. Low
pDC levels conferred an independent negative impact on overall (P = 0.025) and progression-free survival (P = 0.036).
Even before relapse, a decrease in pDC levels was observed (P = 0.002, correlation coefficient 0.898). High levels of
circulating MDSCs (>4.13%) have an independent negative prognostic impact on OS (P = 0.012). MDSC levels were
associated with decreased CD3+ (P < 0.001) and CD3 + CD8+ (P = 0.017) T-cell levels. Conversely, patients with
high MDSC levels had more PD-L1+ T-cells (P = 0.033) and more CTLA-4 expression by Tregs (P = 0.003). pDCs and
MDSCs were inversely correlated (P = 0.004). The impact of pDC levels on prognosis and prediction of the presence
of systemic disease was stronger than that of MDSC levels.
Conclusion: We demonstrated that circulating pDC and MDSC levels are inversely correlated but have an independent
prognostic value in melanoma patients. These cell types represent a single immunologic system and should be
evaluated together. Both are key players in the immunological climate in melanoma patients, as they are correlated
with circulating cytotoxic and regulatory T-cells. Circulating pDC and MDSC levels should be considered in future
immunoprofiling efforts as they could impact disease management.
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Melanoma is a highly immunogenic tumour that is
capable of successfully evading the patients’ immune
response. Evidence for an anti-tumoral immune reaction,
as well as concomitant immunosuppressive mechanisms,
can already be observed in the primary tumour and in
tumour-free sentinel lymph nodes [1,2]. The possibility
to integrate immune markers in the existing TNM-
classification is currently being investigated in melan-
oma. The primary objective is to increase prognostic
accuracy but it could also become a strategy to pre-
select patients for adjuvant therapies [3]. Immunoprofiling
initiatives such as the “Immunoscore” focus on markers in
the primary and metastatic tumour site, mainly assessed
by immunohistochemistry [4]. However, options to evalu-
ate the immune status in a tumour-free patient during
clinical follow-up are currently lacking. In this context,
circulating biomarkers could be a practical approach.
In melanoma, it is at present unclear which circulating
immune cell types confer the most powerful prognostic
information. Besides T-cells, myeloid-derived suppressor
cells (MDSCs) and dendritic cells (DCs) are the most
elaborately studied circulating cell types, but research is
often focused on the tumour microenvironment.
MDSCs are HLA-DR- lineage- CD33+ CD11b + cells
that do not constitute a defined subset of cells but rather
a group of phenotypically heterogeneous myeloid cells
that have a common biological activity [5]. Two clinically
relevant subsets have been defined, monocytic (CD14+)
and polymorphonuclear (CD14-CD15+) MDSCs (resp.
mMDSCs and pmnMDSCs). An expanding body of
evidence shows increased levels of MDSCs in almost all
cancer types, correlating with advanced clinical cancer
stage and a worse prognosis [6,7]. Myeloid differenti-
ation is often disturbed in cancer patients, leading to an
accumulation of immunosuppressive immature myeloid
cells such as MDSCs and reduced frequencies of mature,
immunostimulatory dendritic cells (DCs) [8,9]. Tumour-
derived factors are thought to inhibit the natural differ-
entiation of immature myeloid cells, resulting in the
accumulation of MDSCs [5]. This concomitant increase
in MDSCs and decrease in mature DCs in the periph-
eral blood has been described in several cancer types
[10]. High MDSC frequencies in the peripheral blood of
melanoma patients have also been reported to have a
negative impact on prognosis, but their relation to
dendritic cells or lymphocytes is not well documented.
DCs are potent antigen-presenting cells that play a
central role in developing anti-tumour immune re-
sponses. Two subsets of DCs have been defined in the
blood and in lymphoid tissues, myeloid (CD11c+) and
plasmacytoid (CD123+ CD11c-) DCs (resp. mDCs and
pDCs) [9,11]. Additional surface markers for blood
DCs exist; BDCA-1 and −3 define two distinct subsetsof mDCs and BDCA-2 and BDCA-4 are present on
pDCs. Many other surface markers further characterize
these cells, as recently reviewed elsewhere [11,12]. The
differentiation capacity of DCs is diminished in many
cancers, resulting in lower frequencies of circulating
mature DCs in patients with higher tumour stages or
active disease [9,13,14]. In melanoma, circulating DC
frequencies have been reported to be unchanged in
stage I-III patients [13,14], and reduced in stage IV
[14-16]. Similar patterns in DC alterations have been
described in breast, liver, head and neck and lung
cancer [10,17-19]. However, data on circulating DCs
frequencies in untreated melanoma patients are limited
and their prognostic relevance is unknown. The in vivo
clinical relevance of these circulating subsets in melan-
oma therefore remains subject to debate [8].
Despite evidence that lymphoid cell types such as
cytotoxic and regulatory T-cells are important in melan-
oma and are modulated by current immunotherapeutic
strategies [20], many recent studies on circulating cell
types in melanoma have focused on MDSCs alone and
have left their relation to lymphoid cell types largely
unexplored. The presence of regulatory T-cells (Tregs)
in the melanoma tumour microenvironment confers a
negative prognosis [21]. However, the prognostic rele-
vance of circulating Tregs in untreated melanoma
patients is unclear. Cytotoxic T-cells are powerful allies
in the anti-tumoral immune response and their presence
in the melanoma micro-environment is protective [1],
but data on circulating cell frequencies in untreated
patients are scarce.
Even in stage I and II melanoma a shift in systemic
immune activity can be present and these systemic
immune alterations have been reported to increase as
patients develop metastatic disease. Many different cell
types have separately been described in this context, but
there is no consensus on which alterations have the
predominant immunosuppressive effect. We therefore
performed a comparative evaluation of the presence
of different circulating immune subsets in untreated
melanoma patients in different stages of disease, with a
focus on DCs and MDSCs. The clinical relevance of
circulating DC and MDSC subsets and their relation
with regulatory and cytotoxic T-cells was assessed.
Methods
Patients
Sixty-nine patients with melanoma were included in this
study, with a median follow-up time of 39 months after
diagnosis and of 15 months after inclusion (inclusion
was defined as the time of sample procurement). Venous
blood samples were drawn during clinical follow-up,
with a median interval of 21 months after diagnosis.
Disease staging was done according to the 2009 American
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ease was defined as AJCC stage I and II, regional
disease as AJCC stage III and systemic disease as AJCC
stage IV. The local medical ethical committee ap-
proved this study; all included patients gave written
informed consent. Detailed patient characteristics can
be found in Table 1.
PBMC isolation
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized venous blood by centrifugation
on a Ficoll-Hypaque gradient (GE Healthcare, Uppsala,
Sweden) within 4 h of venepuncture. The PBMCs were
cryopreserved in liquid nitrogen in heat-inactivated
foetal bovine serum (FBS) supplemented with 10%
dimethyl sulphoxide (DMSO) until analysis. Cells were
thawed by submersion at 37° for 1–2 minutes and
resuspended in a medium containing Iscove’s Modified
Dulbecco’s Medium (IMDM) supplemented with 20%
FBS and 1% glutamine.
Flow cytometry
MDSCs were characterized by the HLA-DR- lineage-
(CD3, CD19, CD56) CD33+ CD11b + phenotype, mMDSCs
are CD14+, pmnMDSCs are CD14-. Dendritic cells were
characterized by the HLA-DR+ lineage- (CD3, CD14,
CD16, CD19, CD20, and CD56) phenotype, pDCs are
CD123+ CD11c- and mDCs are CD123- CD11c+. TregsTable 1 Patient characteristics
Number of patients, n
Follow-up time since inclusion, months (median - IQR)
Follow-up time since diagnosis, months (median - IQR)
Age at diagnosis, years (median - IQR)
Female sex, % (n)
Stage at inclusion, % (n)
Local (AJCC stage I & II)
Regional (AJCC stage III)
Systemic (AJCC stage IV)
Active disease at inclusion
Melanoma characteristics
Breslow (median, IQR)
Ulceration, % (n)
Sentinel invasion, % (n)
Location of primary melanoma
Head & neck, % (n)
Trunk, % (n)
Extremities, % (n)
Unknown primary
IQR, interquartile range; AJCC, American joint committee on cancer.were defined as CD3+ CD4+ CD25+ FoxP3+ and cytotoxic
T-cells as CD3+ CD8+ cells. All antibodies used in
this study were fluorescently conjugated mouse anti-
human monoclonal antibodies. The following anti-
bodies were purchased from BD Biosciences; CD3
BV421 (563797), CD4 APC-Cy7 (561839), CD25 FITC
(560990), CD33 BV421 (562854), CD11b APC-Cy7
(560914), CD123 BV421 (562517). The following anti-
bodies were purchased from eBioscience; B7-H1 (PD-L1)
PE-Cy7 (25-5983-42), CD8 APC (9017-0087-025), CD3
FITC (11-0038-41), CD19 FITC (11-0199-41), CD56 FITC
(11-0569-41), CD14 APC (17-0149-41), CD11c APC
(17-0116-41), HLA-DR PerCP-Cy5.5 (45-9956-42). For
intracellular stainings, after surface staining PBMCs
were fixed and permeabilized using Live/dead® fixable
aqua dead cell stain (BD Biosciences), and then stained
with antihuman CTLA-4 APC (BD Biosciences, 560938)
and FoxP3 PerCP-Cy5.5 (eBioscience, 45-4776-42) anti-
bodies. Live/dead staining was performed using an aqua
Dead Cell Stain kit (Life Technologies Europe, Ghent,
Belgium). Patients with less than 75% living cells were
excluded (n = 4). Cells were analyzed on a FACS Canto™ II
flow cytometer (BD Bioscience, Erembodegem, Belgium)
using FlowJo software (Tree Star Inc, Ashland, OR, USA).
For setting the gates, isotype and fluorescence-minus-one
(FMO) controls were used. To provide a representative
sample a median amount of 500000 cells were analysed
(min 261000 – max 569750). Absolute cell counts were69
15 (6–35)
39 (20.5–108)
53 (41.5 – 60)
53.6 (37/69)
46.4 (32/69)
37.7 (26/69)
15.9 (11/69)
20.3 (14/69) (3 stage III, 11 stage IV)
1.60 (1.08 – 2.60)
35.7 (20/56)
27.1 (16/59)
10.6 (7/69)
39.4 (26/69)
50 (33/69)
3 (3/69)
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cytometry. Samples with less than 100000 cells were
excluded (n = 1).
Statistical analysis
Median values between 2 groups were compared by
the Mann–Whitney U-test, between >2 groups with
Kruskall-Wallis testing. To compare proportions of
categorical variables, the Pearson’s Chi2 test or Fisher’s
Exact test were used. To evaluate correlations, Spearman
correlation coefficients (CC) were calculated. To assess
prognostic relevance of continuous variables, ROC curve
analysis was used to dichotomize them with the aid
of the online tool “cut-off finder” [22]. All statistical
analyses were performed using SPSS 21.0 (SPSS Inc,
Chicago, IL, USA), a P-value (double-sided) less than
0.05 was considered statistically significant.
Results
Flow cytometry was performed to quantify MDSC and
DC subsets, Tregs and cytotoxic T-cells in PBMCs from
melanoma patients (Table 1). Table 2 summarizes the
mean detected cell frequencies for all cell types, and the
cut-off points for the dichotomized cell frequencies that
were used in Cox regression models. As a first step, all
immune subsets were compared for their relevance with
regard to clinical variables such as disease stage and
outcome. This showed us that both pDCs and MDSCs
are associated with disease stage and have an impact on
prognosis. Therefore further analyses were focused on
these cell types, as outlined below.
Myeloid-derived suppressor cells (MDSCs)
Melanoma patients with systemic disease have signifi-
cantly higher frequencies of circulating MDSC (P = 0.046).
There was a trend towards higher MDSC frequencies inTable 2 Frequencies of circulating immune subsets in melano
Cell type Cell frequency
(mean % - SD)*
Dendritic cells (DC) 1.54 (0.54)
Plasmacytoid DCs 0.34 (0.18)
Myeloid DCs 0.96 (0.40)
Myeloid-derived suppressor cells (MDSC) 4.00 (2.29)
Monocytic MDSC 2.94 (2.81)
Polymorphonuclear MDSC 1.04 (0.64)
CD3+ cells 43.60 (9.32)
Cytotoxic T-cell 14.79 (6.06)
Regulatory T-cell 4.77 (1.35)
CTLA-4 expression by Tregs 92.32 (4.01)
DC, dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T-cell; SD
* Percentage of live cells, except for Tregs (percentage of CD4+ cells).patients with active disease at time of inclusion, but this
did not reach significance (Figure 1).
High levels of circulating MDSCs (>4.13%) conferred
a negative impact on OS (Log Rank test, P = 0.002).
This effect was independent of disease stage (Figure 2,
P = 0.012, HR 4.77, CI 1.42-16.04). There was no im-
pact of MDSC frequency on progression-free survival
(PFS, Figure 2). Patients who died of melanoma after
inclusion showed a trend towards more circulating
MDSCs at the time of inclusion (P = 0.073).
The relation of MDSCs with the systemic immune context
To further evaluate how MDSCs are related to systemic
immunity, their relation to cytotoxic T-cells and Tregs
was also assessed (Table 3).
The frequency of CD3+ cells was inversely correlated
with MDSCs (P < 0.001, CC −0.519), mMDSCs (P < 0.001,
CC −0.454) and pmnMDSCs (P = 0.004, CC −0.349). The
cytotoxic T-cell frequency was also inversely correlated
with MDSCs (P = 0.017, CC −0.294). On the other hand,
there was a positive correlation between PD-L1+ cytotoxic
T-cells and MDSCs (P = 0.033, CC 0.263), mainly observed
in pmnMDSCs (P = 0.008, CC 0.323). These data suggest
that high MDSC frequencies are associated with relative
lymphopenia and with an immune climate that is unfavor-
able for cytotoxic T-cells.
The percentage of MDSCs was inversely correlated
with the percentage of Tregs (P = 0.007, CC −0.327).
However, the proportion of highly CTLA-4-positive
Tregs was positively correlated with the percentage of
MDSCs (P = 0.002, CC 0.365) and mMDSCs (P = 0.008,
CC 0.321). This was also the case for the mean fluores-
cence intensity (MFI) of CTLA-4 and MDSCs (P =
0.029, CC 0.266). These data suggest that high MDSC
frequencies are associated with a higher suppressive
capacity of circulating Tregs, but not with higher Treg
frequencies.ma patients
Dichotomization
cut-off (%)*
Patients with “high”
cell levels (%)
0.2515 66.7
4.13 33.3
40.25 68.2
93.7 37.3
, standard deviation.
Figure 1 pDC and MDSC frequencies according to melanoma stage and activity. Box-and-whisker plots showing variations in the levels of
circulating myeloid-derived suppressor cells (MDSCs; A and B) and plasmacytoid dendritic cells (pDCs; C and D) according to the presence of
systemic or active disease at the time of inclusion. Circulating cell frequencies are expressed as a percentage of live peripheral blood mononuclear
cells (PBMCs).
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a trend towards more circulating highly CTLA-4+ Tregs
(P = 0.081). A high percentage of CTLA-4 positivity in
circulating Tregs (>93.7%) conferred a negative progno-
sis (Log Rank test, P = 0.003), independent of disease
stage (P = 0.040, HR 3.80, CI 1.06-13.70).
Plasmacytoid dendritic cells (pDCs)
Melanoma patients with systemic disease have signifi-
cantly lower frequencies of circulating pDCs (P = 0.001).
This decrease in pDCs was also seen in patients with
active disease at the time of inclusion (P = 0.002) (Figure 1).
In patients who were disease-free at the time of inclusion
but who presented with disease relapse or progression in
the months after inclusion, a decline in pDCs frequency
could already be seen. The shorter the time frame between
inclusion and relapse, the lower the observed frequency of
pDCs (P = 0.002, CC 0.898).
A low amount of circulating pDCs (<0.2515%) had a
negative prognostic impact on OS, independent of
disease stage (Figure 2; P = 0.025, HR 4.17, CI 1.20-14.52).
In patients who were disease-free at the time of inclusion,
low frequencies of circulating pDCs were also associatedwith a shorter PFS, independent of disease stage (Figure 2;
P = 0.036, HR 10.29, CI 1.162-90.90).
The relation of pDCs with the systemic immune context
To further evaluate the impact of pDCs on systemic
immunity, their relation to Tregs and cytotoxic Tcells was
also assessed by flow cytometry. An inverse correlation
between pDC frequency and the percentage of PD-L1+
cytotoxic T-cells was found (P = 0.044, CC −0.249). No
correlation with Treg frequency or CTLA-4 expression
was detected.
Clinical relevance of MDSCs compared to pDCs
There was no inverse relation between the frequency of
DCs and MDSCs in general. However, when evaluating
the relationship between MDSC and DC subtypes, a
significant inverse correlation was found between pDCs
and MDSCs (P = 0.004, CC −0.338). This was due to an
increase in the absolute number of mMDSCs (P = 0.010,
CC −0.307), not pmnMDSCs. The observed changes in
pDC and MDSC frequencies in patients with systemic
disease were also reflected by an alteration of the
MDSC/DC ratio (P = 0.048). These data suggest that low
Figure 2 Impact of pDC and MDSC frequency on overall and progression-free survival. Cox regression analysis of overall (A and C) and
progression-free (B and D) survival according to the levels of circulating plasmaytoid dendritic cells (A and B) or myeloid-derived suppressor cells
(C and D), after adjustment for disease stage. Time is defined as follow-up time since blood sample procurement. Percentages should be interpreted
as percentages of live peripheral blood mononuclear cells (PBMCs).
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ation of myeloid cells, and an accumulation of MDSCs.
To assess the relative importance of pDCs and MDSCs
with regard to prognosis (impact on OS), a combined
Cox regression model was made (Table 4, upper part).
MDSC and pDC frequencies had a similar impact on
OS, independent of each other and of disease stage.
When CTLA-4+ Treg levels or CD3+ T-cell frequencies
were separately added to this model, both lost their
effect on prognosis, whereas pDCs did not (P = 0.008
for adding CTLA-4, P = 0.019 for adding CD3). These
results indicate that circulating myeloid cells (principally
pDCs) have a superior impact on prognosis (OS) com-
pared to T-cells.
As pDCs and MDSCs emerge as the most prognostic-
ally relevant cell types, we next assessed their relative
importance to each other in predicting the presence of
systemic disease. As indicated in Table 4 (lower part), alogistic regression model was made. A low pDC
frequency at the moment of inclusion could predict
the presence of systemic disease, independent of the
patients’ stage at the time of inclusion and independent
of MDSC frequency. MDSC frequency itself had no
significant predictive quality.
Discussion
Various systemic immune alterations have been de-
scribed in melanoma patients, but a direct comparison
of their clinical relevance is often lacking. In this study,
we demonstrated that an increased amount of circulat-
ing MDSCs and a decreased number of pDCs were asso-
ciated with systemic disease and had both independent
negative prognostic value, although they were inversely
correlated. Both MDSCs and pDCs were linked with
T-cell anergy. Nonetheless, pDCs and MDSCs were the
most prognostically relevant cell types.
Table 3 Association of myeloid-derived suppressor cells
(MDSCs) and plasmacytoid dendritic cells (pDCs) with
melanoma disease course and circulating immune markers
MDSCs pDCs
Melanoma activity and
prognosis
Systemic disease Increased (P = 0.046) Decreased (P = 0.001)
Active disease Increased (P = 0.095) Decreased (P = 0.002)
Death Increased (P = 0.073) Decreased (P = 0.009)
Other immune markers
CD3 cells Inverse (P < 0.001) None
CD8 cells Inverse (P = 0.017) None
PD-L1+ CD8 cells Positive (P = 0.033) Inverse (P = 0.044)
Regulatory T-cells Inverse (P = 0.007) None
CTLA-4 expression in Tregs Positive (P = 0.003) None
PD-L1, Programmed-Death Ligand 1; CTLA-4, Cytotoxic T Lymphocyte-
Associated Antigen 4; Treg, regulatory T-cell.
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were seen in stage IV melanoma patients, which is in
accordance with previous publications [23-25]. The
accumulation of MDSCs in melanoma is most prominent
in stage IV patients, but has been reported as early as
stage I [26]. Most authors agree that MDSCs are upreg-
ulated in melanoma patients compared to healthy
controls [23,25,26]. Whether pmnMDSCs or mMDSCs
dominate depends on the cancer type. Based on litera-
ture and the observations made in this patient set,
mMDSCs appear to have higher impact in melanomaTable 4 Combined Cox (upper part) and logistic (lower part)
regression models comparing circulating myeloid-derived
suppressor cells and plasmacytoid dendritic cells in
melanoma patients
Combined Cox regression model: pDC vs MDSC & overall survival
Coefficient P-value HR 95% Confidence
Interval for HR
Lower Upper
Stage at inclusion 1.87 <0.001 6.46 2.39 17.46
MDSC frequency −1.61 0.009 4.98 1.50 16.67
pDC frequency 1.49 0.019 4.42 1.27 15.33
Logistic regression model: pDC and MDSC & systemic disease
Coefficient P-Value OR 95% Confidence
Interval for OR
Lower Upper
Stage at diagnosis −0.702 0.407 0.496 0.095 2.601
MDSC frequency −0.248 0.753 0.78 0.167 3.655
pDC frequency 1.741 0.032 5.705 1.159 28.091
pDC, plasmacytoid dendritic cell; MDSC, myeloid-derived suppressor cell; HR,
hazard ratio; OR, odds ratio.[27,28]. A negative impact of high CD14- and CD14+
MDSCs on OS and PFS was previously described in
stage IV melanoma patients [25,29]. Significant increases
in circulating MDSC frequencies have also been detected
in the blood of patients with a.o. glioblastoma, breast,
colon, lung and kidney cancer [5,30].
We observed significantly lower circulating pDC fre-
quencies in stage IV melanoma patients. The changes
in total DC frequencies in advanced melanoma have
previously been attributed to pDCs rather than mDCs
[14,15]. Accordingly, we did not observe significant
changes in mDC frequencies, contrary to reduced pDC
levels in stage IV patients. Remarkably, we observed
that a decline in pDC levels had a negative prognostic
effect on both OS and PFS, independent of disease
stage or other cell frequencies. Previous studies have
reported a negative prognostic effect of the presence of
pDCs within the tumour site [31,32], but to our know-
ledge this is the first study to report an independent
negative prognostic effect of low circulating pDC fre-
quencies in untreated melanoma patients. Moreover,
low pDC frequencies were not only associated with a
decreased PFS, but were also already reduced up to a
year before relapse was clinically diagnosed, suggesting
that low pDC frequencies could have a predictive value
in disease-free patients. A possible explanation is that
pDC frequencies are regulated by the tumour itself and
that this regulation takes place very early in the meta-
static process. Alternatively, the observed low pDC
frequencies could also be an indicator of a failing anti-
tumoral immune response, making the patient more
susceptible to relapse. The relevance of pDC frequen-
cies in detecting early disease progression should be
further investigated in prospective trials with longitu-
dinal follow-up samples.
Our data demonstrate a disturbed myeloid differenti-
ation in melanoma, resulting in an accumulation of
MDSCs and a decline in pDCs. To our knowledge, there
are no studies directly reporting this effect in melanoma
patients yet. The independent prognostic effect of both
pDCs and MDSCs suggests that even a partial dysfunc-
tion of myeloid differentiation is sufficient to negatively
influence melanoma disease course. In our dataset, the
effect of pDCs on OS and PFS outweighs that of MDSCs
(Table 4). An alternative interpretation could be that
MDSC frequency is related to the actual tumour load,
whereas adequate pDCs levels could also have a pro-
tective effect on disease progression. Regardless of
which myeloid cell type dominates over the other dur-
ing the course of the disease, it is clear that the myeloid
lineage is globally altered in melanoma as a single
system involving both differentiated myeloid cells and
their pathologically activated immature progenitors [30].
Additionally, our combined Cox regression model showed
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cells dominates over circulating cytotoxic T-cells and to
a lesser extent regulatory T-cells, as the latter two lose
their impact on prognosis when adjusting for pDC or
MDSC frequencies.
Over the last few years, immunoprofiling efforts are
increasing as immunotherapeutic strategies are gaining
importance in the management of melanoma and other
cancers. Several (combinations of) markers with predict-
ive or prognostic quality have been suggested, mainly
focusing on the tumour microenvironment [4,33]. Based
on our data, we conclude that circulating pDCs and
MDSCs should be considered in future prognostic pro-
filing studies. One limitation of our study in this respect
is the use of cryopreserved PBMC samples, which im-
pedes a direct comparison with studies using fresh whole
blood samples. MDSCs have already been investigated as
possible predictive biomarkers for immunotherapy in
melanoma and other malignancies. Low mMDSC levels
were associated with clinical response and improved OS
in melanoma patients treated with ipilimumab [34,35].
Moreover, mMDSC levels have been reported to be
inversely correlated with the presence of tumour-specific
T-cells and with a CD8+ T-cell rise on ipilimumab ther-
apy [29,36]. The inverse correlation between mMDSC
and (antigen-specific) cytotoxic T-cell levels that has
been observed in independent studies including ours
[37], also raises the question whether mMDSC-related
immune suppression could be limiting the therapeutic
benefit of ipilimumab. Alternatively, high mMDSC levels
could also be a marker for deficient myeloid cell matur-
ation leading to a pDC deficit that hampers efficient
immune activation after ipilimumab therapy.
Recently, Schilling and colleagues reported that
mMDSC frequencies decline in patients who have a re-
sponse to vemurafenib and rise again when progressive
disease occurs. The inhibitory effect of vemurafenib on
mMDSCs was present in vitro as well as in vivo [38].
Finkelstein and colleagues reported that high DC/MDSC
ratios and low pretreatment MDSC levels could predict
response to high-dose IL-2 therapy in patients with
melanoma and renal cell carcinoma [39]. In our patient
cohort, pDC frequencies had the highest impact on
prognosis. Furthermore a gradual decline in pDCs levels
seemed to occur before relapse, but as this was a cross-
sectional study these data need to be confirmed in a
longitudinal study with multiple follow-up samples dur-
ing disease course. However, our data do suggest that
pDCs might also be valuable candidates in predictive
immune profiles. The prominent prognostic role of
circulating pDCs also warrants further research into
possible therapeutic strategies, for example with Toll-
like receptor stimulating drugs which have been shown
to enhance pDC activation in the skin [40].Conclusions
Plasmacytoid dendritic cells (pDC) and myeloid-derived
suppressor cells (MDSC) in the peripheral blood should
be regarded as one system and thus be evaluated
together. Both are key players in the immunological
climate in melanoma patients, as they are correlated
with circulating cytotoxic and regulatory T-cells. The
independent prognostic impact of pDCs and MDSCs
makes these cell types attractive for future prognostic
and possibly even predictive immunoprofiling efforts.
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